Press release
North America & Europe PEGylated Drugs Market: Key Players are Merck, Roche, Biogen, Pfizer, Amgen, UCB, AstraZeneca, Sigma-tau & Shire
PEGylated Drugs Market
Request for a sample of this research report @ https://www.fractovia.org/request-sample/963
With the prominence of cancer, arthritis and other chronic disorders imposing the need for high efficacy medications, the North America and Europe PEGylated drugs market earned over USD 7.7 billion in 2017. Supporting the necessity for advanced therapeutic treatments are the statistics from the American Cancer society, which say that more than 15.5 million Americans are suffering from cancer with an anticipated 1.7 million new cases to be reported in 2018. Subsequently, developed nations such as the U.S. receive the largest share of investments in healthcare sector along with witnessing a spurt of biotech and biopharmaceutical start-ups. Phenomenal response has been garnered from government agencies and research organizations regarding acceptance of PEGylated drugs for improving the delivery of therapeutic treatments. Owing to the effective application in chemotherapy and availability of multiple FDA approved treatments, the North America and Europe PEGylated drugs industry is pegged as one of the most lucrative healthcare verticals, with cancer having contributed over 60% to the industry revenue in 2017.
Growth Drivers:
1. Increasing prevalence of cancer in developed regions
2. Rising R&D spending by biotechnology & pharmaceutical companies in U.S. and Europe
3. Growing biologics sector in the developed economies
To understand the implications of the cancer segment in defining the North America and Europe PEGylated drugs market, in 2015 about 1.3 million or 26% of all deaths in Europe resulted from cancer, making it the second biggest cause of fatalities in the EU. The upsurge in cigarette smoking and pollution along with unhealthy dietary consumption among EU population is expected to increase the frequency cancer and other chronic diseases. Consequently, the advantages of PEGylated drugs in improving treatments has inspired a number of companies in the region to develop bio-conjugated drugs, strengthening the North America and Europe PEGylated drugs industry.
Browse Full Report @ https://bit.ly/2uqvF2R
Elaborating on the significance of North America and Europe PEGylated drugs market, a slew of PEGylated drug delivery systems such as Neulasta, Onivyde and PEG intron are employed in various cancer treatments, with additional drugs in the pipeline or pending approvals. For instance, the U.S. Food and Drug Administration (FDA) accepted a biologics license application from Shire PLC, a biotech leader in rare diseases, for Calaspargase Pegol (Cal-PEG) as a component of antineoplastic combination therapy for acute lymphoblastic leukemia (ALL) patients. The development is based on Shire’s research and experience with ONCASPAR (pegaspargase), a first-line treatment for ALL approved in the U.S. According to reports on the efficiency and safety of Cal-PEG, if approved it will permit availability of treatments that have a prolonged shelf life beyond the current PEGylated asparaginase treatment.
Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
1. Merck
2. Roche
3. Biogen
4. Pfizer
5. Amgen
6. UCB
7. AstraZeneca
8. Sigma-tau
9. Shire
10. Novo Nordisk
About Fractovia:
Fractovia.org is one of leading in-house and free news portal. It is fully automated, and operates on a constant premise, interfacing with news sites and offering redesigned breaking features to readers across the globe. Our mission is to offer individuals opportunities for connections with news writers and distributors which they can pursue. We operate by mapping articles pertaining to breaking news, constantly and progressively, against a pre-determined word-based theme, offering important connections to readers and clients, as well as distributors.
Contact Us:
1968 S. Coast Hwy #586,
Laguna Beach CA 92651,
USA
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release North America & Europe PEGylated Drugs Market: Key Players are Merck, Roche, Biogen, Pfizer, Amgen, UCB, AstraZeneca, Sigma-tau & Shire here
News-ID: 1152096 • Views: …
More Releases from fractovia.org
Non-alcoholic Beer Market Key Players are Heineken, Suntory, Bernard Family Brew …
Owing to a worldwide escalation in the preference for low liquor content beverages, the non-alcoholic beer market size has proliferated at an outstanding pace over the past decade. This has been complemented with the fact that the disposable incomes among the global middle-class population have shot up which has further provided a commendable boost to the overall non-alcoholic beer industry. The rising consolidation and maturation of this business space can…
Food Protein Ingredients Market key players are ADM, Cargill, DuPont, Bunge, Mea …
Food protein ingredients market has lately witnessed a profitable trajectory, pertaining to the changing relationship of consumers with food due to increasing urbanization and greater disposable incomes. Taking the rapidly increasing global populace into consideration, which incidentally according to the UN, will surpass 9.5 billion, it is rather obvious that consumption patterns will undergo an eventual change. With the changes that will follow in the dietary preferences, experts anticipate food…
Food Enzymes Market Trends 2018 with Key Players of this Industry are BASF, DSM, …
Danish food enzymes market major Chr. Hansen, has recently announced that it will be expanding its West Allis plant that produces enzymes that are freeze-dried and shipped all over the world. The enzymes go into yogurt, cheese, and other food, as well as in animal feed, baby formula, probiotic supplements, and natural dyes. Allegedly, this latest expansion by Hansen to increase the production capacity and add new capabilities to its…
Dental Osseointegration Implants Market Major Key Players are Zimmer Biomet, Str …
Having already experienced monetary returns from a slew of imperative collaborations since the last few years, osseointegration implants market has now observed yet another partnership that would help increase its overall remuneration. The reputed American producer of dental equipment consumables, Dentsply Sirona has recently announced a partnership with Zephyr Sleep Technologies.
Request for a sample of this research report @ https://www.fractovia.org/request-sample/642
This alliance has been apparently aimed at generating potentially new…
More Releases for PEG
Biopharma PEG Delivers Innovative PEG Solutions for Enhanced Drug Efficacy
Watertown, MA - October 24, 2024 - Biopharma PEG is excited to announce its extensive offerings of polyethylene glycol (PEG) products, including monofunctional, homobifunctional, heterobifunctional, and multi-arm PEGs, tailored for PEGylation in biopharmaceutical applications. With over 40 PEGylated drugs approved globally, the role of PEGylation in drug development is more critical than ever.
PEGylation provides numerous advantages, such as improved solubility, enhanced stability, and increased circulation time in the bloodstream. By…
Biopharma PEG Expands Multi-Arm PEG Product Line
Biopharma PEG, a leader in PEG derivatives, is excited to announce the expansion of its high-purity Multi-Arm PEG linker product line, catering to the evolving needs of the medical and bioorganic fields. These advanced PEG linkers are available in various functional groups and molecular weights ranging from 1k to 40k, offering unmatched versatility and performance for research and development in cutting-edge medical applications.
"Biopharma PEG is committed to delivering high-purity multi-arm…
Biopharma PEG Supplies PEG Products Used For Infectious Disease Vaccines
As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development.
Recombinant protein vaccines accounted for the largest proportion of all pipeline in development, 22% (215), due…
Biopharma PEG Supplies PEG Products For Click Chemistry Reactions
What is "click chemistry"? "Click Chemistry", this is a literary name given to this kind of reaction by the Nobel Prize winner K.Burry Sharless, when the cards are put together, "click" (click). Simply put, it is to add two structures to two molecules respectively, and these two structures can be specifically combined to synthesize the required chemical molecules. One of the most famous click-chemistry reactions is the Cu-catalyzed azide-alkyne cycloaddition…
Biopharma PEG Develops PEG Linkers for Antibody Drug Conjugates
Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody (Antibody), linker (Linker) and active drug (Payload). So far, there are only 15 drugs on the market in the world. However, with the development of some perfect antibody modification techniques, advanced site-specific coupling techniques and powerful small-molecule toxins, ADC drug research has mushroomed and a large number of ADC drugs are in…
Biopharma PEG Provides Multi-arm PEG Derivatives Crosslinked Into Hydrogels
Polyethylene (ethylene glycol) is a hydrophilic polymer that can have a very high water content when cross-linked into a network. Polyethylene glycol (PEG) is a suitable material for biological applications because it does not normally elicit an immune response. Since the 1970s, PEG has been used to modify therapeutic proteins and peptides in order to increase their solubility, reduce their toxicity, and prolong their cyclic half-lives. In the late 1970s,…
